health insurance glp 1 GLP-1 Medication: Understanding Your Options Insurance companies scrambling to support

2.4% placebo SURMOUNT-1 weight loss / up to 22.5% mean reduction at 72 weeks with tirzepatide 15 mg HbA1c in normoglycemic participants / dropped 0.2 to 0.5 percentage points in major GLP-1 trials SELECT cardiovascular benefit / 20% reduction in MACE with semaglutide 2.4 mg over 3.4 years median follow-up SCALE Obesity and Prediabetes / liraglutide 3.0 mg reduced new-onset type 2 diabetes by 79% over 3 years in prediabetic participants Fasting insulin reduction / 20 to 40% decreases observed across STEP and SURMOUNT programs Current ADA guidance / pharmacotherapy recommended as adjunct to lifestyle for adults with obesity What "Before Prediabetes" Actually Means A person can carry significant metabolic risk without meeting the laboratory cutoffs for prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7% to 6.4%)

In clinical studies of cagrilintide plus semaglutide, greater average weight loss was observed than with semaglutide alone, although individual results vary and side effects can also increase with combination therapy

GIP: glucose-dependent insulinotropic polypeptide

The peptide binds directly to these cells and triggers regenerative responses

It is acetylated and amidated to improve the peptide's stability and pharmacokinetics